CBM light up lives mid banner advert
Advertisement: Hewitsons mid banner
Advertisement: Kao Data Centre mid banner
ARM Innovation Hub
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement – Charles Stanley mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Howard Group mid banner
Advertisement: EY Mid banner
Advertisement: Mogrify mid banner
Advertisement mid banner S-Tech 1
Advertisement: RSM
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
4 May, 2021 - 09:49 By Tony Quested

Mogrify closes $33m Series A to scale transformative tech globally

Cambridge’s world leading cell therapy pioneer Mogrify has taken its Series A round to $33 million with a $17m second closing.

The company is transforming the development of ex vivo cell therapies and steering a new class of in vivo reprogramming therapies. 

The new cash will support the advancement of Mogrify’s immuno-oncology and ophthalmology programs, as well as continued platform development and the exploration of cell reprogramming for novel therapeutic application.

This second close of the company’s Series A was led by Parkwalk Advisors and incorporates additional funding from strategic corporate pharma investor Astellas Venture Management as well as 24Haymarket, co-founder of Abcam Dr Jonathan Milner and Mogrify CEO, Dr Darrin Disley.

Proceeds will be used to advance Mogrify’s immuno-oncology and ophthalmology programs, inclusive of iPSC-derived allogeneic cell therapies targeting hematological and solid malignancies, as well as in vivo reprogramming therapies aiming to address retinal degeneration, a leading cause of blindness, through to IND-enabling studies.

Mogrify’s proprietary suite of platform technologies enable systematic identification of the key transcriptomic and epigenetic cell switches that drive the speed, efficiency and maintenance of cellular reprogramming. 

In addition to the company’s core programs, the broad potential of both the MOGRIFY® and epiMOGRIFY technologies allow continued exploration and generation of novel cell-based and in vivo reprogramming therapies for disease areas with high unmet clinical need.

Mogrify also announced the appointments of Dr Lorenz Mayr, former CTO of GE Healthcare Life Sciences and VP for Discovery Sciences at AstraZeneca, as Non-Executive Director, after serving as an observer since July 2020, and Dr Hiromichi Kimura, Astellas Venture Management as an Observer.

CEO Darrin Disley said: “We are delighted to see the continued support of our existing investors as well as welcome new investors Astellas Venture Management and Dr Jonathan Milner, in support of the progression of our initial programs through to IND-enabling studies.

“Their commitment is a testament to our delivery of world-class science, expertise in cellular reprogramming and the unique potential of the MOGRIFY and epiMOGRIFY platforms to develop novel in vivo reprogramming therapies while also addressing issues of scalability and manufacturing in ex vivo cell therapies. 

“This latest funding will provide runway toward a significant Series B round as we progress our lead assets toward the clinic.”

Alastair Kilgour, chief investment officer, Parkwalk Advisors, said: “Mogrify is led by a team with proven world-class commercial and scientific expertise who have made significant progress in applying the technology to drive the speed, efficiency and maintenance of cellular reprogramming. 

“We are excited to continue supporting their extraordinary team as the company progresses with increasing success in cell and gene therapy development.”

• PHOTOGRAPH: CEO Darrin Disley (left) with colleagues in the  senior management team, from left: Dr Rodrigo Santos, director of Cell Technologies; Professor Julian Gough (co-founder and CSO); Dr Karin Schmitt (chief business officer); Joe Foster (chief operating officer); Pierre-Louis Joffrin (corporate development executive). Picture by Phil Mynott.

Newsletter Subscription

Stay informed of the latest news and features